EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective

Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.763
https://www.valueinhealthjournal.com/article/S1098-3015(23)03893-7/fulltext
Title : EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03893-7&doi=10.1016/j.jval.2023.09.763
First page :
Section Title :
Open access? : No
Section Order : 10249
Categories :
Tags :
Regions :
ViH Article Tags :